ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable
Thomas H. Brannagan(Columbia University), Frederick L. Ruberg(Boston University), Nowell M. Fine(University of Calgary), Morie A. Gertz(Medical University of South Carolina), John L. Berk(Boston University), Hartmut Schmidt(Université Paris-Sud), Márcia Waddington‐Cruz(Université Paris-Sud), Mazen Hanna(Cleveland Clinic), Jacqueline Shehata(Akebia Therapeutics (United States)), Chiara Briani(University of Padua), Luís F. Quintana(Hospital Clínic de Barcelona), Andrew M. Rosen(Akebia Therapeutics (United States)), Hanna K. Gaggin(Massachusetts General Hospital), David R. Hurwitz, Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Matthew J. Maurer(Mayo Clinic in Arizona), Carol Whelan(The Royal Free Hospital), Brian Drachman(Penn Presbyterian Medical Center), Thibaud Damy(Amyloidosis Foundation), Kemi Olugemo(Akebia Therapeutics (United States)), Vera Bril(University Health Network), Sami Khella(University of Lisbon), José Nativi-Nicolau(Jacksonville College), Angela Dispenzieri(Mayo Clinic), Teresa Coelho(Universidade do Porto), Michaela Auer‐Grumbach(Vienna General Hospital)
Cited by 16
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k